JWM
VRTX icon

Jackson Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Jackson Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,502
Closed -$1.41M – 178
2024
Q4 		$1.41M Sell
3,502
-46
-1% -$21.3K 0.16% 82
2024
Q3 		$1.65M Buy
3,548
+1,682
+90% +$808K 0.2% 79
2024
Q2 		$875K Sell
1,866
-1,689
-48% -$733K 0.19% 82
2024
Q1 		$1.49M Buy
3,555
+46
+1% +$19.4K 0.19% 79
2023
Q4 		$1.43M Buy
3,509
+56
+2% +$20.7K 0.19% 78
2023
Q3 		$1.2M Sell
3,453
-62
-2% -$21.7K 0.17% 80
2023
Q2 		$1.24M Buy
3,515
+67
+2% +$22.6K 0.18% 75
2023
Q1 		$1.09M Buy
+3,448
New +$1.03M 0.82% 46
2022
Q4 		– Sell
-4,880
Closed -$1.41M – 110
2022
Q3 		$1.41M Buy
4,880
+3,187
+188% +$917K 0.28% 69
2022
Q2 		$477K Buy
+1,693
New +$453K 0.22% 77

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Jackson Wealth Management's VRTX Position: Q1 2025 in Review

Jackson Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 3,502 shares — an estimated $1.41M sold.

Jackson Wealth Management first reported a position in VRTX in Q2 2022 and held it in 10 quarters. The position peaked at $1.65M in Q3 2024. 1,616 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Jackson Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Jackson Wealth Management sold 3,502 Vertex Pharmaceuticals shares in Q1 2025, an estimated $1.41M.
  • Jackson Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Jackson Wealth Management's Vertex Pharmaceuticals position peaked at $1.65M in Q3 2024.
  • 1,616 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Jackson Wealth Management's 13F filing for Q1 2025, filed 29 Apr 2025.